Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.

中文翻译：

---

利用聚合物-脂质杂化纳米粒子进行靶向抗癌治疗

癌症是最危险的疾病之一，全世界有 180 万人死亡。尽管传统疗法取得了显着进步，但这些疗法并不能有效彻底根除癌症。纳米技术基于多种纳米粒子 (NP) 的配方提供了潜在的癌症治疗方法。脂质体和聚合物纳米颗粒是用于癌症治疗的研究最多且最有效的药物递送系统（DDS）。脂质体因其独特的特性而代表了潜在的 DDS，包括高药物包封功效、生物相容性、低成本和可扩展性。然而，它们的使用受到对脂质过氧化的敏感性、不稳定性、药物爆发释放和有限的表面修饰的限制。类似地，聚合物纳米粒子表现出多种聚合物化学修饰、良好的稳定性和受控释放，但其生物应用的缺点包括载药量有限、聚合物毒性和放大困难。因此，聚合物纳米颗粒和脂质体结合形成聚合物-脂质杂化纳米颗粒（PLHNPs），具有两种组分的积极属性，例如高生物相容性和稳定性、改善的药物有效负载、受控的药物释放、更长的循环时间和优异的体内功效。在这篇综述中，我们重点关注用于开发肿瘤靶向 PLHNP 的重要策略，并讨论它们有助于实现理想 DDS 的优势和独特特性。